New potential of the treatment of atopic dermatitis in children and adults
- 作者: Proshutinskaya DV1, Butareva MM1, Inoyatova LA1
-
隶属关系:
- State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation
- 期: 卷 89, 编号 3 (2013)
- 页面: 78-82
- 栏目: Articles
- URL: https://ogarev-online.ru/0042-4609/article/view/117086
- DOI: https://doi.org/10.25208/vdv618
- ID: 117086
如何引用文章
全文:
详细
Goal. To study the efficacy and safety of local administration of Tacrolimus in the form of 0.03% and 0.1% ointment for patients with moderate to severe atopic dermatitis. Materials and methods. The study involved 32 patients suffering from atopic dermatitis and aged 2—64. The first group comprised 17 children aged 2—15 (7 girls and 10 boys). The second group comprised 15 patients (8 female and 7 male) aged 18—64. All of the patients suffered from moderate to severe atopic dermatitis. Patients from both treatment groups received external therapy in the form of 0.03% of ointment for children and 0.1% of ointment for adults. The daily ointment amount was calculated as FTU (Finger Tip Units) for separate body parts. To ensure objective assessment of the severity of clinical manifestations of atopic dermatitis and treatment efficacy, SCORAD (Severity Scoring of Atopic Dermatitis) score was used for all of the patients. Results. The treatment resulted in a statistically significant reduction in the medial SCORAD index from 67.2 (54.8; 70.4) points to 14.0 (3.5; 22.1) points (р < 0.0001), Group 1, and from 52 (43.5; 75.5) points to 11.7 (0.0; 26.2) points (р < 0.0001), Group 2. Clinical recovery was achieved in 30% of children and 40% of adults. Conclusion. Protopic ointment for the treatment of patients with moderate to severe atopic dermatitis proved to be highly efficient, which was confirmed by a positive therapeutic effect on the course of the disease. There were no adverse effects characteristic of topical corticosteroids, which widens horizons in terms of treating patients with this type of dermatosis.
作者简介
D Proshutinskaya
State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation
Email: detstvo@cnikvi.ru
д.м.н, ведущий научный сотрудник, заведующая отделением детской дерматологии Korolenko str. 3, bldg 6, Moscow, 107076, Russia
M Butareva
State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federationк.м.н., заведующий дневным стационаром Korolenko str. 3, bldg 6, Moscow, 107076, Russia
L Inoyatova
State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federationврач-дерматовенеролог отделения детской дерматологии, аспирант Korolenko str. 3, bldg 6, Moscow, 107076, Russia
参考
- Кубанова А.А. Анализ эпидемиологической ситуации по заболеваемости инфекциями, передаваемыми половым путем, болезнями кожи и подкожной клетчатки населения Российской Федерации, по данным официальной государственной статистки. Вестн дерматол и венерол 2о08; (5): 8—18.
- Williams H.C., Atopic Dermatitis. The epidemiology, Causes and Prevention of Atopic Eczema. Cambridge University Press, Cambridge, UK, 2000.
- Hanifin J.M., Cooper K.D., Ho V.C., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD) American Academy of Dermatology Association «Administrative Regulations for Evidence-Based Clinical Practice Guidelines». J Am Acad Dermatol. 2004; 50: 391—404.
- Емельянов А.В., Монахов К.Н. Топические кортикостероиды в терапии аллергодерматозов: значение внегеномного эффекта. Вестн дерматол и венерол 2002; (3): 59—61.
- Кубанова А.А., Самсонов В.А., Авербах Е.В., Тимошин Г.Г. Элоком в лечении больных псориазом и атопическим дерматитом. Вестн дерматол и венерол 1996; (5): 10—12.
- Гребенюк В.Н., Балаболкин И.И. Прогресс в наружной кортикостероидной терапии атопического дерматита у детей. Педиатрия. 1998; (5): 88—91.
- Berth-Jones J., Damstra R.J., Golsch S., et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367.
- Leung D.Y., Hanifin J.M., et al. Disease management of atopic dermatitis: a practice parameter. Ann Allergy Asthma Immunol 1997; 79: 197—211.
- Satoshi Takeuchi, M.D., Ph.D., Hidehisa Saeki, M.D., Ph.D.2, Shoji Tokunaga. A. Randomized, Open-Label, Multicenter Trial of Topical Tacrolimus for the Treatment of Pruritis in Patients with Atopic Dermatitis.Ann Dermatol 2012; 24; (2): 144—150.
- Reitamo S., Rustin M., Ruzicka T., Cambazard F., Kalimo K., Friedmann P.S. et al; European Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547—555.
- Antonello Baldo, Mariana Cafiero, Paola Di Caterino. Tacrolimus ointment in the management of atopic dermatitis. Clin Cosmet Investi Dermatol 2009: 2: 1—7.
- Japanese FK-506 Ointment Study Group. Phase III study of FK-506 (Tacrolimus) ointment in patients with atopic dermatitis -Comparison study with 0.12% betamethasone valerate ointment for trunk and extremities lesions-. Nishinihon J Dermatol 1997; 59: 870—879.
- Короткий Н.Г., Тихомиров А.А., Гамаюнов Б.Н. и др. Новые возможности наружной терапии тяжело протекающих форм атопического дерматита у детей. Педиат фармакол 2011; 8: 6: 96—102.
- Кунгуров Н.В., Кохан М.М., Кенинксфест и др. Проактивная наружная терапия больных атопическим дерматитом детей и взрослых—новый, эффективный тактический подход. Вестн дерматол и венерол 2012; 3: 15—120.
- R.S. Kirsner, M.P. Heffernan. Safety and Efficacy of Tacrolimus Ointment Versus Pimecrolimus Cream in the Treatment of Patients with Atopic Dermatitis Previously Treated with Corticosteroids. Acta Derm Venereol 2010; 90: 58—64.
- Kang S., Paller A., Soter N. Safe treatment of head/neck AD with Tacrolimus ointment. J of Dermatological Treatment 2003; 14, 86—94.
补充文件
